Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982253 · ClinicalTrials.gov registry record · Phase 2
Fasiglifam 25 mg BID vs 50 mg QD
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01982253 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 10 participants.
The verdict
NCT01982253, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.
Interventions
- DRUG Fasiglifam
- DRUG Placebo to fasiglifam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01982253
The ClinicalTrials.gov registry entry for NCT01982253 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fasiglifam is the first listed.
NCT01982253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01982253 about?
NCT01982253 is a clinical study titled "Fasiglifam 25 mg BID vs 50 mg QD". To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.
What is the current status of trial NCT01982253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-10. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01982253?
The interventions under investigation include: Fasiglifam (DRUG), Placebo to fasiglifam (DRUG).
Who is sponsoring clinical trial NCT01982253?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.